

➤ ***Cost of implementation of malaria vaccination programmes in five select sub-Saharan African countries (Burkina Faso, Ghana, Kenya, Mozambique, Tanzania)***

With the aim of improving prevention of malaria, GSK Vaccines, in partnership with the Malaria Vaccine Initiative (MVI), has been developing during the last decades, the RTS,S/AS01 *Plasmodium Falciparum* malaria vaccine. Safety, efficacy and immunogenicity of RTS,S/AS01 have been tested (phase III trial) across several sub-Saharan African countries. Following the results of phase III trial, the file for this vaccine has been recently given regulatory approval by the European Medicines Agency (EMA). In order to translate the candidate vaccine into health policy in a context of competing health problems and of limited financing, an economic evaluation is needed in which incremental costs and health benefits of malaria vaccination are compared with the current preventative strategies. This research aimed at estimating the cost of implementation of RTS,S malaria vaccination programmes in five sub-Saharan African countries, all with a GAVI status: Burkina Faso, Ghana, Kenya, Mozambique and Tanzania. Dr. Nonvignon was the Ghana country PI for the study while Elisa Sicuri, Barcelona Centre for International Health Research, country-PIs for Burkina Faso, Kenya, Mozambique, Tanzania. The amount involved is EUR 60,000.00 provided by GSK Vaccines,